Considering the high heterogeneity of vitamin D signaling in breast cancer, it is unknown whether vitamin D resistance through VDR methylation or CYP24A1 amplification during tumor progression would emerge for one individual’s breast cancer9. The gene discussed is VDR; the disease is breast cancer.